CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS

Organization Name

Inventor(s)

Kendall Carey of South San Francisco CA (US)

CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18636947 titled 'CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS

The present invention offers a cell-based assay to identify and quantify anti-CD3 homodimers in a composition containing a T cell-dependent Bispecific antibody (TDB). T cells with a T cell activation responsive reporter are used to detect the presence of anti-CD3 homodimers when contacted with the TDB. Compositions of reporter T cells and kits are also included.

Cell-based assay for identifying and quantifying anti-CD3 homodimers
Use of T cells with a T cell activation responsive reporter
Detection of anti-CD3 homodimers in the presence of TDB
Compositions of reporter T cells and kits provided
Potential applications in drug development and immunotherapy

- Potential Applications:**

This technology can be used in drug development to assess the efficacy of TDBs and other immunotherapies. It can also aid in research on T cell activation and signaling pathways.

- Problems Solved:**

This technology addresses the need for a reliable method to detect and quantify anti-CD3 homodimers in the presence of TDBs, which is crucial for understanding the mechanisms of action of these therapeutic agents.

- Benefits:**

The cell-based assay provides a sensitive and specific way to measure anti-CD3 homodimers, allowing for better characterization of TDBs and their effects on T cell activation. This can lead to improved drug development and personalized medicine approaches.

- Commercial Applications:**

Title: Cell-Based Assay for Anti-CD3 Homodimers: Commercial Uses and Market Implications This technology has potential commercial applications in pharmaceutical companies, biotechnology firms, and research institutions involved in immunotherapy and drug development. It can streamline the process of evaluating TDBs and other immunotherapies, leading to more effective treatments for various diseases.

- Questions about Cell-Based Assay for Anti-CD3 Homodimers:**

1. How does the cell-based assay compare to traditional methods of detecting anti-CD3 homodimers? 2. What are the implications of accurately quantifying anti-CD3 homodimers in the context of TDBs and immunotherapy?

Original Abstract Submitted

The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.